Duvelisib was the second PI3K inhibitor accepted because of the FDA, also based on a stage III randomized demo.a hundred thirty The efficacy and safety profile of the drug look similar with All those of idelalisib, Otherwise a little bit advantageous. Relating to different BTK inhibitors, there are